<SEC-DOCUMENT>0001387131-16-007014.txt : 20160919
<SEC-HEADER>0001387131-16-007014.hdr.sgml : 20160919
<ACCEPTANCE-DATETIME>20160919172249
ACCESSION NUMBER:		0001387131-16-007014
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160919
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160919
DATE AS OF CHANGE:		20160919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		161892501

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_091916.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 14pt; text-transform: none">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"></P>

<HR ALIGN="CENTER" NOSHADE STYLE="color: Black; width: 30%; height: 1pt; margin-top: 0; margin-bottom: 0">
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 14pt">FORM
8-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center">SECURITIES
EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Date of Report (Date of earliest event
reported): September 19, 2016</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 14pt"><B>TherapeuticsMD,
    Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 30pt; text-align: center">(Exact Name of Registrant as Specified
in its Charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: Black 1pt solid; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>6800 Broken Sound Parkway NW,</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Third Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Boca Raton, FL 33487</B></P></TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant's
telephone number, including area code: (561) 961-1900</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (<I>see</I> General Instruction A.2 below):</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>                                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>                                                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>                                                                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt/1pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: -1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
2.02.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results of Operations and Financial Condition.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
Inc. is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a press release on September 19, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 2.02 and shall not be deemed
to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this Current Report, regardless of any general incorporation language in the filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any
change in events, conditions, or circumstances on which any forward-looking statement is based.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
text included with this Current Report on Form 8-K is available on our website located at www.therapeuticsmd.com, although we
reserve the right to discontinue that availability at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01.&#9;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(d)</TD>
    <TD STYLE="width: 1in"><I>Exhibits.</I></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Exhibit <BR>
    <U>Number</U></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>99.1</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release from TherapeuticsMD, Inc., dated September 19, 2016, entitled &#8220;TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy&#8482; (TX-004HR)&#8221;</FONT></P>
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date:&nbsp;&nbsp;September 19, 2016</TD>
    <TD COLSPAN="3">THERAPEUTICSMD, INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="width: 26%; border-bottom: Black 1pt solid">/s/ <I>Daniel A. Cartwright</I></TD>
    <TD STYLE="width: 18%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">Daniel A. Cartwright</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Financial Officer </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">(d)</TD>
    <TD STYLE="width: 1in"><I>Exhibits.</I></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Exhibit <BR>
    <U>Number</U></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>99.1</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release from TherapeuticsMD, Inc., dated September 19, 2016, entitled &#8220;TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy&#8482; (TX-004HR)&#8221;</FONT></A></P>
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE FROM THERAPEUTICSMD, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><A HREF="txmd-8k_091916.htm"></A></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_091916.htm">TherapeuticsMD 8K</A></P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: right"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 23.25pt; width: 202.5pt"></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TherapeuticsMD Announces FDA Acceptance
of New Drug Application (NDA) and </B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Prescription Drug User Fee Act (PDUFA)
Date for Yuvvexy&trade; (TX-004HR)</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><I>-
</I></B><I>PDUFA target action date of May 7, 2017 <B>-</B></I></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>BOCA
RATON, Florida, Sept. 19, 2016</B> &ndash; TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women&rsquo;s healthcare company,
today announced the acceptance of the NDA for Yuvvexy, the conditionally-approved trade name for TX-004HR, by the U.S. Food and
Drug Administration (FDA). Yuvvexy is an investigational bio-identical 17&beta;-estradiol vaginal softgel capsule for the treatment
of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy (VVA) in postmenopausal
women.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The NDA
acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to permit a substantive review.
The PDUFA target action date for the completion of the FDA's review is May 7, 2017.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;The
acceptance of the NDA for Yuvvexy is an important milestone for TherapeuticsMD as we pursue our goal to provide women with novel
healthcare solutions that address their needs throughout life,&rdquo; said TherapeuticsMD CEO Robert G. Finizio. &ldquo;If approved,
Yuvvexy has the potential to be a highly differentiated treatment option for the 32 million postmenopausal women in the United
States who suffer from symptoms of VVA. Yuvvexy is the first product candidate from our pipeline of novel hormone therapies in
development to address women&rsquo;s unmet health needs.&rdquo;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The 505(b)(2)
NDA submission for Yuvvexy is supported by the complete Yuvvexy clinical program, including positive results of the phase 3 Rejoice
Trial, which evaluated the effect of three doses of Yuvvexy (4 mcg, 10 mcg and 25 mcg) compared to placebo from baseline to week
12. The results demonstrated statistically significant and clinically meaningful improvements in dyspareunia, a co-primary endpoint,
and vaginal dryness, a secondary endpoint. Statistically significant results were seen as early as two weeks of treatment. The
NDA includes all three doses of Yuvvexy that were evaluated in the Rejoice Trial.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About
Yuvvexy</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Yuvvexy
is an applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during
sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About
Vulvar and Vaginal Atrophy (VVA)</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">An estimated
32 million women in the United States are currently suffering from symptoms of VVA, and only 2.3 million (7 percent) are currently
being treated with prescription therapy. VVA symptoms can range from mild to severe and include dyspareunia, vaginal dryness,
urinary tract infections, and vaginal bleeding associated with sexual activity. Vaginal dryness and dyspareunia are considered
the most bothersome symptoms of VVA. Because of the chronic nature of VVA due to menopause, its symptoms will not likely resolve
without intervention.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The burden
of VVA in the United States may increase due to aging of the population. Furthermore, due to increasing longevity, women may now
suffer from VVA or other conditions related to decreased reproductive hormone levels for over one-third of their lives.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About
TherapeuticsMD, Inc. </B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">TherapeuticsMD,
Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA<SUP>&trade;
</SUP>technology, TherapeuticsMD is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones
through a variety of dosage forms and administration routes. The company&rsquo;s clinical development pipeline includes two phase
3 products. The company manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD<SUP>&reg; </SUP>and BocaGreenMD<SUP>&reg;</SUP> brands. More information is available at the following
websites: <FONT STYLE="color: Blue"><U>www.therapeuticsmd.com</U></FONT>, <FONT STYLE="color: Blue"><U>www.vitamedmd.com</U></FONT>
and <FONT STYLE="color: Blue"><U>www.bocagreenmd.com</U></FONT>.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">This
press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are
not limited to, statements relating to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often characterized by terminology such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo;
&ldquo;expects,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar
expressions and are based on assumptions and assessments made in light of management&rsquo;s experience and perception of historical
trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements
in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any
such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important
factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements
are described in the sections titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form
8-K, and include the following: the company&rsquo;s ability to maintain or increase sales of its products; the company&rsquo;s
ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; whether
the FDA will approve the company&rsquo;s new drug application for its TX-004HR product candidate and whether any such approval
will occur by the PDUFA date; the length, cost and uncertain results of the company&rsquo;s clinical trials; the potential of
adverse side effects or other safety risks that could preclude the approval of the company&rsquo;s hormone therapy drug candidates;
the company&rsquo;s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the
availability of reimbursement from government authorities and health insurance companies for the company&rsquo;s products; the
impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading
price of the company&rsquo;s common stock and the concentration of power in its stock ownership. PDF copies of the company&rsquo;s
historical press releases and financial tables can be viewed and downloaded at its website: <FONT STYLE="color: Blue"><U>www.therapeuticsmd.com/pressreleases.aspx</U></FONT>.</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Contact:
</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Investors</U></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">David
DeLucia</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Director,
Investor Relations</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">561-961-1900</FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Blue"><U>David.Delucia@TherapeuticsMD.com</U></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"># # #</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q :8# 2(  A$! Q$!_\0
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M23?&#_M< J/?GWQ7JBLKJ&4AE(R"#D$4IPE!VDAPJ1FKQ8M%<#'\26?XC_\
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M2Y>IG?$;Q]=>"&TX6UC#=?:Q*6\QRNW;MZ8_WJ[+3KIKW3+2[90K3PI(5!R
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MMP;_ -!7\JUM2^"?AIK:22VN;^V=$)'[Q77@=P1G]17.? 8YU;6#_P!.\?\
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M"/<'FN'\):S+X/UJ[\.ZW*([8$O'*Q^53C.1_LL/U]R:]%T7_D Z=_U[1_\
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M3BHQ5D@HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'@'B?_DX"W_Z_P"R_P#08Z]_HHKHK[0]#EP_Q3]0HHHKG.H**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
